Press Releases
2023
Date |
Title |
Details |
19 Sep 2023 |
Oxford BioTherapeutics to Participate in Panel Discussion at Boehringer Ingelheim's upcoming Transforming Science Day: Europe |
View here |
05 Jul 2023 |
Oxford BioTherapeutics Initiates Phase Ib Clinical Trial for OBT076 in Patients with Advanced Solid Tumours by Dosing First Patient in Combination with CPI Balstilimab in Europe |
View here |
25 May 2023 |
Oxford BioTherapeutics and Boehringer Ingelheim Agree on 2 Year Extension to their Second Multi-Year Collaboration in Cancer Immunology |
View here |
19 Apr 2023 |
Oxford BioTherapeutics Announces Phase1b Trial in Collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the Head and Neck |
View here |
09 Mar 2023 |
Oxford BioTherapeutics to Announce New Fully Integrated ADC Engine at the World ADC Conference 2023 |
View here |
07 Mar 2023 |
Oxford BioTherapeutics wins Tech Company of the Year and Special Recognition Award at Thames Valley SME Growth 100 Awards |
View here |
2022
Date |
Title |
Details |
13 June 2022 |
Oxford BioTherapeutics enters into Commercial License Agreement with Genmab |
View here |
13 June 2022 |
Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates |
View here |
27 May 2022 |
Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022 |
View here |
25 May 2022 |
Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in Combination with Agenus CPI Balstilimab |
View here |
13 April 2022 |
Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology target |
View here |
07 April 2022 |
AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076 |
View here |
2021
Date |
Title |
Details |
20 Sept 2021 |
Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic |
View here |
19 Jan 2021 |
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics' WuXiBody® Platform |
View here |
06 Jan 2021 |
Kite and Oxford BioTherapeutics Establish Cell therapy Research Collaboration in Blood Cancers and Solid Tumours |
View here |
2020
Date |
Title |
Details |
14 Oct 2020 |
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic |
View here |
09 Jan 2020 |
Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors |
View here |
2019
Date |
Title |
Details |
25 Jun 2019 |
Oxford BioTherapeutics Announces Receipt of a Milestone Payment as Boehringer Ingelheim Advances an Oncology Drug Candidate |
View here |
2018
Date |
Title |
Details |
21 Dec 2018 |
Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076: An Experimental First in Class ADC Medicine for High Risk Her2 Negative Breast Cancer, Gastric, Lung, Bladder and Ovarian Cancer Patients - US Phase I Clinical Trial to be Initiated |
View here |
11 Dec 2018 |
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million |
View here |
01 Mar 2018 |
Oxford BioTherapeutics Appoints Chief Medical Officer, Abderrahim Fandi |
View here |
2017
Date |
Title |
Details |
13 Jun 2017 |
Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director |
View here |
09 Feb 2017 |
Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans |
View here |
26 Jan 2017 |
Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics |